Participant has relapsed or refractory multiple myeloma with documented evidence of progression that occurred during or after the participant's last treatment regimen based on investigator's determination of International Myeloma Working Group (IMWG) criteria.
Potential subjects with evidence of progressive disease as per International Myeloma Working Group (IMWG) criteria
Multiple myeloma diagnosed according to the International Myeloma Working Group (IMWG) diagnostic criteria
Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG])
Subjects must have documented evidence of progressive disease according to the IMWG uniform response criteria following the last multiple myeloma treatment.
multiple myeloma as per IMWG 2014 definition
Completion of induction therapy with very good partial response (VGPR), or better, by International Myeloma Working Group (IMWG) criteria
Patients with a diagnosis of MM as defined by the 2014 IMWG diagnostic criteria
Diagnosis of relapsed, symptomatic multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma
Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
Evidence of a response (Partial response [PR] or better based on investigator's determination of response by international myeloma working group [IMWG] criteria) to at least 1 prior treatment regimen
Multiple myeloma diagnosis according to the IMWG diagnostic criteria
Diagnosis of multiple myeloma refractory to or relapsed after >= 1 line of prior therapy (International Myeloma Working Group [IMWG] criteria)
Concurrent multiple myeloma (defined according to 2015 International Myeloma Working Group [IMWG] guidelines)
Worsening urinary paraproteinemia will be considered in the context of International Myeloma Working Group (IMWG) disease response criteria on a monthly basis; any patient with urinary protein (otherwise unrelated to urinary myeloma associated monoclonal [M]-protein) with excretion > 3.5 g/day will be considered to have developed nephrotic-range proteinuria, and will be taken off study
Must have a confirmed diagnosis of multiple myeloma (MM) requiring therapy according to International Myeloma Working Group (IMWG) criteria.
Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatment
Subjects with symptomatic multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria who are receiving or have completed induction chemotherapy, who have achieved at least a partial response (PR) on most recent therapy by IMWG criteria, and are eligible for auto-SCT for consolidation; a specific induction regimen is not dictated for this protocol, however, the induction regimen must not have contained melphalan (L-PAM, Alkeran)
Subjects must have a confirmed prior diagnosis of active MM as defined by the International Myeloma Working Group (IMWG) criteria
Measurable relapsed or refractory myeloma as defined by the International Myeloma Working Group (IMWG) Consensus Criteria following treatment with at least 3 lines of therapy including with both a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or progressive myeloma that is refractory to a regimen containing both a PI and an IMiD.
Patients with newly diagnosed multiple myeloma who have at least a partial response after induction therapy based on the International Working Group (IWG) Uniform Response Criteria
Must have a diagnosis of a MM using current International Myeloma Working Group (IMWG) diagnostic criteria and have received 1 prior line of therapy.
Diagnosis of multiple myeloma as per International Myeloma Working Group (IMWG) uniform criteria
Patient with multiple myeloma relapsing according to the International uniform response criteria for multiple myeloma (IMWG 2009/ revised Blad√© criteria) to one previous line of treatment
Have confirmed diagnosis of Multiple Myeloma as defined by the IMWG.
Documented diagnosis of multiple myeloma (MM) based on standard IMWG criteria.
Documented diagnosis of symptomatic multiple myeloma, as defined by the IMWG
Patient has been previously diagnosed with multiple myeloma (MM) based on standard International Myeloma Working Group (IMWG) criteria
Diagnosis and previously untreated active multiple myeloma by International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma
Evidence of multiple myeloma disease progression (as defined by International Myeloma Working Group [IMWG]) any time prior to ASCT
Patients must carry a diagnosis of symptomatic multiple myeloma according to international myeloma working group criteria and have relapsed or refractory disease according to international uniform response criteria after at least two prior treatment regimens including a proteasome inhibitor and an immunomodulator (IMiD)
Diagnosis of MM requiring systemic therapy (per the International Myeloma Working Group [IMWG] ).
Clinically overt multiple myeloma, according to the International Myeloma Working Group (IMWG) criteria with at least 1 of the following:
Measurable disease on Screening per International Myeloma Working Group (IMWG) criteria.
Patient has been previously diagnosed with multiple myeloma (MM) based on standard criteria and currently requires treatment because MM has relapsed following a response, according to International Myeloma Working Group (IMWG) criteria.
All subjects must have documented disease progression per IMWG criteria during or after their last anti-myeloma therapy.
Participants proven to have multiple myeloma (MM) diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
Must have had documented evidence of progressive disease as defined based on Investigator's determination of response of International Myeloma Working Group (IMWG) criteria on or after their last regimen
Evidence of a response (partial response [PR] or better based on investigator's determination of response by International Myeloma Working Group [IMWG] criteria) to at least 1 prior treatment regimen
Patients who at initial diagnosis or later met the International Myeloma Working Group (IMWG) definition of active multiple myeloma requiring therapy (Appendix 3)
Patients must have histologically or cytologically confirmed smoldering multiple myeloma confirmed by Department of Pathology, based on the International Myeloma Working Group Criteria
Patients with a diagnosis of multiple myeloma (MM) per standard International Myeloma Working Group (IMWG) criteria
Participants must have a diagnosis of multiple myeloma (MM) according Revised International Myeloma Working Group diagnostic criteria:
Note: Laboratory assessments used to support the hypercalcemia, renal failure, anemia, bone lesions (CRAB) criteria in the International Myeloma Working Group (IMWG) 2014 diagnostic criteria of MM are performed at the time of diagnosis; these assessments are not required to be performed within the 21 days of initiation of protocol therapy
Confirmed diagnosis of relapsed and/or refractory multiple myeloma (MM) according to International Myeloma Working Group guidelines (2003); refractory disease is defined as documented disease progression during or within 60 days after their most recent line of anti-myeloma therapy
Patients must have a history of symptomatic multiple myeloma according to the International Myeloma Working Group criteria (IMWG, 2003)
Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen
Participants must have a previous diagnosis of MM, according to International Myeloma Foundation 2003 diagnostic criteria
Newly diagnosed, myeloma requiring systemic chemotherapy as per International Myeloma Working Group (IMWG) uniform criteria:\r\n* Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle)\r\n* Bisphosphonates are permitted
Patients must have histologically or cytologically confirmed relapsed multiple myeloma as defined by the International Myeloma Working Group (IMWG)
Diagnosis of active Multiple Myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria
Histologic and serologic findings from Memorial Sloan-Kettering Cancer Center (MSKCC) confirming the diagnosis of multiple myeloma; standard diagnostic criteria for multiple myeloma will be used, as per the revised International Myeloma Working Group diagnostic criteria
Symptomatic multiple myeloma by International Myeloma Working Group (IMWG) criteria according to the most recent updated version (International Myeloma Workshop [IMW] meeting in Paris 2011)
Must have a documented diagnosis of relapsed and refractory multiple myeloma defined by the International Myeloma Working Group (IMWG) criteria.
Patients with progressive or refractory plasma cell myeloma, as defined by International Myeloma Workshop Consensus Panel criteria
Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma
For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects must have histological confirmation of multiple myeloma with measurable\n             disease (per International Myeloma Working Group (IMWG) criteria):\n\n               -  Relapsed/refractory multiple myeloma, subjects who are post autologous transplant\n                  and have achieved very good partial response (VGPR) or complete response (nCR)\n                  with minimal residual disease (MRD)
Newly diagnosed symptomatic multiple myeloma (per International Myeloma Working Group [IMWG] diagnostic criteria)
Diagnosis of symptomatic MM as defined by the International Myeloma Working Group (IMWG) :
Elevated Free Light Chain as per the International Myeloma Working Group (IMWG) criteria
Patient has relapsed or relapsed/refractory MM with measurable disease parameters according to the International Myeloma Working Group (IMWG) Criteria
Patients must have a definitive diagnosis of multiple myeloma (using the International Myeloma Working Group Guidelines)
Participants must have a diagnosis of relapsed multiple myeloma according to standard criteria established by the International Myeloma Working Group
Multiple myeloma or plasma cell leukemia with a PR or better to the last treatment regimen, based on the International Myeloma Working Group (IMWG) criteria
Documented diagnosis of multiple myeloma, currently with complete response (CR) or very good partial response (VGPR) (as defined by International Myeloma Working Group [IMWG] criteria), at least two years after induction therapy or autologous stem cell transplant
Diagnosed with multiple myeloma and in complete, partial or very good partial remission at enrollment as per standard International Myeloma Working Group Criteria
Documentation of r/r MM as defined by the International Myeloma Working Group (IMWG) criteria.
Diagnosis of multiple myeloma with documented relapsed or refractory disease according to international Myeloma Working Group (IMWG) criteria, or relapsed/refractory plasma cell leukemia
